TEL AVIV, Israel, March 5, 2020 /PRNewswire/ -- Galmed
Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a
clinical-stage biopharmaceutical company focused on the development
of Aramchol, a liver targeted, oral, SCD1 modulator, currently in
Phase 3 clinical trial for the treatment of nonalcoholic
steatohepatitis (NASH) and fibrosis announced today that it
will host a conference call and webcast on Thursday, March 12, 2020, to provide an update on
current developments with respect to its clinical programs for
Aramchol™ and to discuss financial results for the
quarter and year ended December 31, 2019.
|
Conference Call
& Webcast:
|
|
Thursday March
12, 2020, 8:30 AM ET
|
|
Toll
Free:
|
1-877-425-9470
|
|
Toll/International:
|
1-201-389-0878
|
|
Israel Toll
Free:
|
1-809-406-247
|
|
Conference
ID:
|
13699345
|
|
Webcast:
|
http://public.viavid.com/index.php?id=138184
|
|
|
|
Replay Dial-In
Numbers
|
|
Toll
Free:
|
1-844-512-2921
|
|
Toll/International:
|
1-412-317-6671
|
|
Replay Pin
Number:
|
13699345
|
|
Replay
Start:
|
Thursday, March 12,
2020, 11:30 AM ET
|
|
Replay
Expiry:
|
Thursday, March 26,
2020, 11:59 PM ET
|
About Aramchol and Non-alcoholic Steatohepatitis
(NASH)
Aramchol (arachidyl amido cholanoic acid) is a novel fatty acid
bile acid conjugate, inducing beneficial modulation of
intra-hepatic lipid metabolism. Aramchol's ability to modulate
hepatic lipid metabolism was discovered and validated in animal
models, demonstrating downregulation of the three key pathologies
of NASH: steatosis, inflammation and fibrosis. The effect of
Aramchol on fibrosis is mediated by downregulation of steatosis and
directly on human collagen producing cells. Aramchol has been
granted Fast Track designation status by the FDA for the treatment
of NASH.
NASH is an emerging world crisis impacting an estimated 3% to 5%
of the U.S. population and an estimated 2% to 4% globally. It is
the fastest growing cause of liver cancer and liver transplant in
the U.S. due to the rise in obesity. NASH is the progressive form
of non-alcoholic fatty liver disease that can lead to
cardiovascular disease, cirrhosis and liver-related mortality.
About Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. is a clinical stage drug development
biopharmaceutical company for liver, metabolic and inflammatory
diseases. Our lead compound, Aramchol™, a backbone
drug candidate for the treatment of NASH and fibrosis is currently
in a Phase 3 registrational study.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-report-fourth-quarter-and-year-end-2019-financial-results-and-provide-business-update-on-thursday-march-12-301017212.html
SOURCE Galmed Pharmaceuticals Ltd.